Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of NYSE BTX opened at $1.09 on Friday. The business has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.81. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The stock has a market capitalization of $64.12 million, a P/E ratio of -0.48 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.